La bruja del lago

[Fyodor Dostoevsky Collection 🪓 @Dostoevskyquot]

This one gets me every time lol

[La Jefita @lajefita]

Tus macrófagos alveolares
Tus células de Kupffer
Tu microglía.
Tus macrófagos del bazo
Tus macrófagos del mesangio glomerular

Todos tus comelones 😍

[EL PAÍS @el_pais]

📹 Cien mil poemas caen del cielo en Barcelona para reivindicar la cultura ante la guerra

[La bruja del lago @_dianalt]

Próximamente se encontrará la forma de quedarnos quietas, todas juntas.

[La bruja del lago @_dianalt]

Adeu.

[La bruja del lago @_dianalt]

Home.

[La bruja del lago @_dianalt]

¿Quién eres tú?

[Stephen Gibbons @Gibboanxious]

Inside Llewyn Davis (2013)

dir. The Coen Brothers

[the pantomathwar @pantomathwar]

Gustav Klimt, Two Studies of a Seated Nude with Long Hair, 1901-02, detail

[La bruja del lago @_dianalt]

No más no me digas pa’ donde te vas.

[Dr Rishabh Jain @DrRishabhOnco]

Interesting signal from #PRIMARY2. 🧵

Can we safely avoid prostate biopsy in men with PI-RADS 2-3 MRI but persistent clinical suspicion of prostate cancer?

🔬 PRIMARY2 (Phase III, Lancet Oncology)

660 biopsy-naïve men with:
• PI-RADS 2-3 MRI
• High clinical risk (PSA density, family history, abnormal DRE, etc.)

Randomized to:
➡️ Standard systematic biopsy
➡️ PSMA PET-guided strategy

📊 Key Results

✅ Clinically significant prostate cancer:
12% vs 16%
Non-inferior with PSMA PET strategy
(p=0.009 for non-inferiority)

✅ Biopsies avoided:
49%

✅ Clinically insignificant cancers:
14% vs 32%
Absolute reduction: 18%

✅ No increase in missed high-grade disease

💡 Takeaway

PSMA PET may become an important biopsy triage tool after equivocal or non-suspicious MRI.

Fewer biopsies.
Less overdiagnosis.
No apparent compromise in clinically significant cancer detection.

If validated globally and shown to be cost-effective, this could meaningfully reshape the prostate cancer diagnostic pathway.

📄 PRIMARY2
Lancet Oncology 2026
DOI: 10.1016/S1470-2045(26)00120-8

#ProstateCancer #PSMAPET #UroOnc #MedTwitter @TheLancetOncol @MSKHofman @LouiseEmmettMD @oncoalert

[Dr Rishabh Jain @DrRishabhOnco]

🚨 Should we still be giving upfront chemotherapy to most high-risk HR+/HER2− metastatic breast cancer patients?

The PADMA trial says probably not.

👩‍⚕️ 120 patients with HR+/HER2− mBC considered candidates for chemotherapy
⚖️ Palbociclib + endocrine therapy vs physician’s choice chemotherapy

📈 Median TTF:
17.2 vs 6.1 months
HR 0.46 (P<0.001)

📈 Median PFS:
18.7 vs 7.8 months
HR 0.45 (P<0.001)

🎯 Benefit was consistent across key subgroups, including patients with liver metastases and those with high disease burden.

⚠️ More hematologic toxicity with palbociclib, but no new safety signals.

💡 Takeaway:
Even in patients for whom clinicians were considering chemotherapy, first-line CDK4/6 inhibitor + endocrine therapy outperformed chemotherapy.

Another reminder that chemotherapy should remain the exception, not the default, in HR+/HER2− mBC.

Full paper link in comment

#bcsm #BreastCancer #MedTwitter #Oncology #ESMOOpen
@oncoalert

[La bruja del lago @_dianalt]

Te estimo Gaudi

[☂️ @oleemequivocao]

que le den por culo a la torre eiffel

[La bruja del lago @_dianalt]

Mañana.

[La bruja del lago @_dianalt]

A la mesa y a la cama
Una vez se llama.

[Fyodor Dostoevsky Collection 🪓 @Dostoevskyquot]

a sentimental love story: